Search research articles
Contact Us
Filters
Showing results (251-260 of 268) with videos related to
Page
of 27
Sort By:
The New England Journal of Medicine
|
May 6, 2014
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
Peter Ferenci, David Bernstein, Jacob Lalezari, et al.
Transplantation and Cellular Therapy
|
November 10, 2025
Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy
C Arianne Buchan, Gerard Agbayani, Katrina Hueniken, et al.
The International Journal on Drug Policy
|
November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Jason Grebely, Brian Conway, Evan B Cunningham, et al.
Blood Advances
|
January 27, 2026
Immunogenicity and Safety of a Third and Subsequent COVID-19 Vaccine Doses in Patients with Plasma Cell Dyscrasias
Sita Bhella, Gerard Agbayani, Katrina Hueniken, et al.
The International Journal on Drug Policy
|
October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study
Evan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Journal of Hepatology
|
June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Sergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
The Lancet. Gastroenterology & Hepatology
|
January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
Jason Grebely, Olav Dalgard, Brian Conway, et al.
The New England Journal of Medicine
|
July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 10, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
Markus Cornberg, Homie A Razavi, Alfredo Alberti, et al.
The New England Journal of Medicine
|
November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 268) with videos related to
Sort By:
Page
of 27
The New England Journal of Medicine
|
May 6, 2014
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
Peter Ferenci, David Bernstein, Jacob Lalezari, et al.
Transplantation and Cellular Therapy
|
November 10, 2025
Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy
C Arianne Buchan, Gerard Agbayani, Katrina Hueniken, et al.
The International Journal on Drug Policy
|
November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Jason Grebely, Brian Conway, Evan B Cunningham, et al.
Blood Advances
|
January 27, 2026
Immunogenicity and Safety of a Third and Subsequent COVID-19 Vaccine Doses in Patients with Plasma Cell Dyscrasias
Sita Bhella, Gerard Agbayani, Katrina Hueniken, et al.
The International Journal on Drug Policy
|
October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study
Evan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Journal of Hepatology
|
June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Sergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
The Lancet. Gastroenterology & Hepatology
|
January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
Jason Grebely, Olav Dalgard, Brian Conway, et al.
The New England Journal of Medicine
|
July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 10, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
Markus Cornberg, Homie A Razavi, Alfredo Alberti, et al.
The New England Journal of Medicine
|
November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Page
of 27